CV8 THE COST-EFFECTIVENESS (COST-UTILITY) OF EPROSARTAN IN HYPERTENSIVE PATIENTS WITH CEREBROVASCULAR DISEASE IN BELGIUM, GERMANY, SPAIN, UNITED KINGDOM, AND SWEDEN
Abstract
Authors
B Schwander P Lindgren B Gradl
B Schwander P Lindgren B Gradl
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now